Profile data is unavailable for this security.
About the company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
- Revenue in USD (TTM)29.94m
- Net income in USD-104.77m
- Incorporated2001
- Employees123.00
- LocationMersana Therapeutics Inc840 Memorial DrCAMBRIDGE 02139-3789United StatesUSA
- Phone+1 (617) 498-0020
- Fax+1 (302) 655-5049
- Websitehttps://www.mersana.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | 0.00 | -49.99m | 246.41m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Rezolute Inc | 0.00 | -58.21m | 247.66m | 51.00 | -- | 2.73 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| 2Seventy Bio Inc | 44.12m | -156.25m | 250.79m | 274.00 | -- | 1.07 | -- | 5.68 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Abeona Therapeutics Inc | 0.00 | -52.60m | 251.22m | 84.00 | -- | 3.30 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Trevi Therapeutics Inc | 0.00 | -38.77m | 254.07m | 25.00 | -- | 3.84 | -- | -- | -0.3879 | -0.3879 | 0.00 | 0.9116 | 0.00 | -- | -- | 0.00 | -44.37 | -47.39 | -47.48 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0014 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 258.30m | 449.00 | -- | 2.68 | -- | 1.83 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 268.66m | 123.00 | -- | 31.88 | -- | 8.97 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -80.55m | 270.09m | 54.00 | -- | 2.43 | -- | -- | -1.54 | -1.54 | 0.00 | 1.97 | 0.00 | -- | -- | 0.00 | -59.70 | -40.29 | -67.82 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Vanda Pharmaceuticals Inc. | 182.02m | -10.93m | 271.05m | 203.00 | -- | 0.4996 | -- | 1.49 | -0.1886 | -0.1886 | 3.15 | 9.31 | 0.2815 | 9.96 | 4.82 | 896,660.10 | -1.69 | 6.61 | -1.97 | 7.62 | 93.03 | 90.55 | -6.00 | 15.18 | 4.67 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 274.23m | 14.00 | -- | 1.75 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Chromadex Corp | 85.58m | -1.35m | 280.95m | 106.00 | -- | 9.09 | -- | 3.28 | -0.018 | -0.018 | 1.14 | 0.407 | 1.60 | 2.86 | 12.93 | 807,386.80 | -2.52 | -42.11 | -3.85 | -65.14 | 60.82 | 59.68 | -1.58 | -30.64 | 2.12 | -- | 0.0006 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| AVITA Medical Inc | 54.14m | -49.83m | 281.47m | 207.00 | -- | 11.75 | -- | 5.20 | -1.95 | -1.95 | 2.12 | 0.9216 | 0.6217 | 1.46 | 7.23 | 261,541.10 | -57.22 | -- | -68.00 | -- | 86.80 | -- | -92.04 | -- | 4.81 | -13.95 | 0.6315 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 284.89m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 287.51m | 50.00 | -- | 2.23 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Akebia Therapeutics Inc | 174.50m | -40.44m | 288.09m | 167.00 | -- | -- | -- | 1.65 | -0.2024 | -0.2024 | 0.8803 | -0.1608 | 0.7364 | 1.36 | 7.07 | 1,044,892.00 | -17.07 | -37.42 | -29.47 | -56.00 | 82.59 | 69.13 | -23.18 | -82.25 | 0.8222 | -4.41 | 8.89 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Mersana Therapeutics Inc's reporting currency: US Dollar USD
42.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 30 Jun 2024 | 19.36m | 15.79% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 7.50m | 6.11% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 6.55m | 5.34% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 3.05m | 2.48% |
| Schonfeld Strategic Advisors LLCas of 30 Jun 2024 | 2.98m | 2.43% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.68m | 2.19% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.66m | 2.17% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 2.60m | 2.12% |
| SilverArc Capital Management LLCas of 30 Jun 2024 | 2.50m | 2.04% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.49m | 2.03% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
